placebo for inhalation

BIOLOGICAL2 trials

Sponsors

University of Oxford, CanSino Biologics Inc.

Conditions

COVID-19Influenza

Phase 1

Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation

CompletedNCT04840992

CanSino Biologics Inc.COVID-19

Start: 2021-04-21End: 2022-08-09Updated: 2023-02-08

Phase 4

Long Term Influenza Prophylaxis With Inhaled Zanamivir or Oral Oseltamivir

CompletedNCT00980109

University of OxfordInfluenza

Start: 2009-09-30End: 2010-09-30Updated: 2010-09-22

Related Papers

Vaccination with Adenovirus Type 5 Vector-Based COVID-19 Vaccine as the Primary Series in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 1/2 Clinical Trial

Vaccines2024-03-116 citations

Environmental Impact Assessment for the Use of an Orally Aerosolized Adenovirus Type-5 Vector-Based COVID-19 Vaccine in Randomized Clinical Trials

The Journal of Infectious Diseases2023-05-181 citations